Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2022-03-09 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于和元生物技术（上海）股份有限公司首次公开发行股票并在科创板上市战略投资者核查事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the verification of strategic investors for a company's initial public offering (IPO) and listing on the STAR Market (科创板). It discusses the qualifications, shareholding, and commitments of strategic investors participating in the IPO. The document references regulatory frameworks related to securities issuance and underwriting, and details the strategic placement of shares to specific investors. It is not a financial report, earnings release, or management discussion, but a legal opinion related to the IPO process and strategic investor verification. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal document related to the IPO and does not fit other categories such as Annual Report, Earnings Release, or Capital/Financing Update. The document length is substantial and contains detailed legal and regulatory content, not just an announcement or a brief notice, but it is not a financial report itself.
2022-03-09 Chinese
海通证券股份有限公司、国泰君安证券股份有限公司关于和元生物技术（上海）股份有限公司首次公开发行股票战略配售之专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report issued by the lead underwriters (保荐机构) and co-underwriters regarding the strategic placement (战略配售) for the initial public offering (IPO) of shares of a company (和元生物技术（上海）股份有限公司). It includes extensive information about the strategic investors, their qualifications, share allotments, compliance with regulatory guidelines, and legal opinions. The document references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange, and discusses the strategic placement process in detail. This is not an announcement of a report, nor a transcript, nor a financial statement. It is a specialized verification report related to the IPO strategic placement, which fits the category of an Audit Report / Information (AR) as it involves a formal verification and compliance check by the underwriters and legal counsel. The document length and detail confirm it is a full report, not a brief announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2022
2022-03-09 Chinese
和元生物首次公开发行股票并在科创板上市网上路演公告
Investor Presentation Classification · 95% confidence The document is titled as an "网上路演公告" which translates to "Online Roadshow Announcement" related to the company's initial public offering (IPO) and listing on the STAR Market (科创板). It details the underwriting institutions, issuance structure, and the schedule for the online roadshow event. The document does not contain financial statements or detailed financial analysis but serves as an announcement to investors about the roadshow event and the IPO process. The document length is short (1470 characters), and it is clearly an announcement rather than a full report or presentation. Therefore, it fits best under the category of Investor Presentation (IP) since roadshows are presentations aimed at investors to explain the offering and company details.
2022-03-08 Chinese
和元生物首次公开发行股票并在科创板上市招股意向书
Regulatory Filings Classification · 95% confidence The document is a detailed prospectus (招股意向书) for an initial public offering (IPO) on the Shanghai Stock Exchange's STAR Market (科创板). It includes extensive information about the company's business, risks, financial data, management, and other disclosures typical of an IPO prospectus. The document is not an annual report, earnings release, or any other routine financial report. It is a formal offering document used to inform potential investors about the company and the stock issuance. This type of document corresponds to a prospectus or offering document, which is not explicitly listed in the provided categories. However, the closest and most appropriate category for IPO prospectuses and offering documents is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and filings that do not fit other categories. Therefore, the document should be classified as Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is a full filing, not a brief announcement or certification.
2022-03-02 Chinese
和元生物首次公开发行股票并在科创板上市招股意向书附录
Capital/Financing Update Classification · 95% confidence The document is a detailed issuance prospectus and sponsorship letter related to the initial public offering (IPO) and listing of Obio Technology (Shanghai) Corp., Ltd. on the STAR Market (科创板). It includes extensive information about the underwriting institution, company background, shareholding structure, compliance with regulatory requirements, and detailed financial and operational data. The document is not a simple announcement but a comprehensive filing related to the IPO process, including audit reports and legal opinions as appendices. This type of document is characteristic of a Capital/Financing Update (CAP) filing, as it pertains to the company's fundraising and capital structure changes through the IPO. It is not an Annual Report, Earnings Release, or other categories. Therefore, the correct classification is Capital/Financing Update (CAP).
2022-03-02 Chinese
和元生物首次公开发行股票并在科创板上市发行安排及初步询价公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of shares by 和元生物技术（上海）股份有限公司 on the Shanghai Stock Exchange's STAR Market (科创板). It includes extensive information about the issuance arrangement, preliminary inquiry, strategic placement, underwriting, pricing, subscription conditions, lock-up periods, and timelines related to the IPO process. The document references regulatory approvals from the China Securities Regulatory Commission (证监会) and compliance with various regulatory rules and guidelines for IPOs on the STAR Market. It also details the roles of the lead underwriters, strategic investors, and the subscription process for institutional investors. The document is not a financial report, earnings release, or management discussion but rather an official announcement of the IPO issuance arrangements and preliminary pricing inquiry. This type of document fits the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising and capital structure changes through the IPO process.
2022-03-02 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.